ClinicalTrials.gg
CompletedNCT02052739SRSEUpdated Sep 15, 2025Results posted

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

A Phase 1/2 interventional study of SAGE-547 in Super-refractory Status Epilepticus, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 17 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.

Enrollment
17th of 30
25 · median 35
Started
2014
with 2 others
Phase 1/2
Only one
of the 41
Registered
8th of 41
by date
Lead sponsor
2 of 41
Supernus Pharmaceuticals, Inc.

Among the 41 studies in Status Epilepticus with a site in United States, this one is the 17th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2014, is the only one in phase 1/2, and was the 8th registered.

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

Browse Status Epilepticus studies →

Open to participants now

13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Status Epilepticus with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Read the detailed description

This is an open-label study consisting of a screening period (1 day), 4-day treatment period (96 hours) followed by a 1-day dose taper period (24 hours), a 2-day acute follow-up period, and a 3 week extended follow-up period.

On Day 1 of treatment SRSE participants under seizure suppression or burst-suppression with a continuous intravenous (IV) anti-epileptic drug (AED) (third-line agent) were given a 1-hour IV loading infusion of SAGE-547 followed by a maintenance infusion. After 48 hours of SAGE-547 treatment, the continuous IV AED (third-line agent) was weaned while continuing SAGE-547 at the maintenance infusion for the remainder of the treatment period. After 96 hours (4 days) of therapy with SAGE-547, the dose was to be tapered and discontinued over 24 hours.

The participants would have routine continuous electroencephalogram (EEG) monitoring during the screening period, and continuing until 48 hours after SAGE-547 treatment had completed. Participants would then have follow-up examinations weekly for the next 3 weeks (Days 8, 15, 22, and 29), during which safety and functional assessments would be obtained. Apart from treatment with SAGE-547, all participants would receive the standard of care for adults in SRSE along with ongoing treatment for all underlying medical conditions.

03

Conditions studied

  • Super-refractory Status Epilepticus

Browse trials for

Keywords

  • Status Epilepticus
  • Refractory status epilepticus
  • Super-refractory status epilepticus
  • SAGE-547
  • SAGE
  • Sage Therapeutics
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 2 years of age and older.
  • Participants with an EEG-confirmed SRSE diagnosis under concomitant therapy with a continuous IV AED ( agent) for ≥ 24 hours. For this study, SRSE is defined by the following criteria and in accordance with those used at major epilepsy treatment centers:

    • Failure to respond to the administration of at least one first-line agent (e.g., benzodiazepine or other emergent initial AED treatment), according to institution standard of care, and
    • Failure to respond to at least one second-line agent (e.g., phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control AED) according to institution standard of care, and
    • Presence of one or more breakthrough seizures > 6 hours after initiation of the continuous IV AED/third-line agent (e.g., pentobarbital, midazolam, propofol).

Exclusion criteria

Exclusion Criteria:

  • Participants with SRSE due to anoxic/hypoxic encephalopathy, children (participants aged less than 18 years) with an encephalopathy due to an underlying progressive neurological disorder.
  • Participants with abnormalities.
  • Participants with a significant medical or surgical condition that may compromise vital organ systems, or other conditions that would place the participants at increased risk such as dialysis or acute respiratory distress syndrome, severe cardiogenic or vasodilatory shock requiring 2 or more pressors, fulminant hepatic failure, etc.
  • Participants who are receiving a continuous IV AED ( agent) for seizure suppression or burst-suppression that would require greater than 24 hours to wean.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    SAGE-547 Standard Dose

    Participants received SAGE-547 IV loading infusion of 286.6 micrograms per kilogram per hour (μg/kg/hr) for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5.

    Drug: SAGE-547

  • Experimental
    SAGE-547 High Dose

    Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5.

    Drug: SAGE-547

Interventions

  • Solution for injection for IV infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs are defined as those that begin on or after initiation of the infusion of SAGE-547.

    Time frame: Up to Day 29

  2. Change From Baseline (CFB) in National Institutes of Health Stroke Scale (NIH-SS) Total Score

    The National Institutes of Health Stroke Scale (NIH-SS) was used to examine the physical and neurological state of the participants. The NIH-SS is a 15-item assessment with measures of level of consciousness, visual gaze and vision loss, facial palsy, motor ability, ataxia, sensory ability, aphasia, dysarthria, and inattention. The total NIHSS score range is from 0 (normal) to 42 (severe impairment), with higher values indicating greater level of neurological impairment.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  3. Change From Baseline in Vital Sign Parameter: Body Weight

    Vital signs included weight, heart rate, blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), respiratory rate, temperature, oxygen saturation. CFB in body weight is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  4. Change From Baseline in Vital Sign Parameter: Heart Rate

    Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in heart rate is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended Follow-up at Days 8, 15, 22 and 29

  5. Change From Baseline in Vital Sign Parameter: Blood Pressure - SBP and DBP

    Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in SBP and DBP is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72: 72 hour;73-96: 96 hour;97-120:120 hour;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8,15,22 and 29

  6. Change From Baseline in Vital Sign Parameter: Respiratory Rate

    Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in respiratory rate is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8, 15, 22 and 29

  7. Change From Baseline in Vital Sign Parameter: Body Temperature

    Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in body temperature is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  8. Change From Baseline in Vital Sign Parameter: Oxygen Saturation

    Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. Oxygen saturation is a measure of how much hemoglobin is currently bound to oxygen compared to how much hemoglobin remains unbound. CFB in oxygen saturation is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  9. Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in alanine aminotransferase levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  10. Change From Baseline in Serum Chemistry Parameter: Albumin Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in albumin levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  11. Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in aspartate aminotransferase levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  12. Change From Baseline in Serum Chemistry Parameter: Bicarbonate Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bicarbonate levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  13. Change From Baseline in Serum Chemistry Parameter: Bilirubin Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bilirubin levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  14. Change From Baseline in Serum Chemistry Parameter: Blood Urea Nitrogen Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in blood urea nitrogen levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  15. Change From Baseline in Serum Chemistry Parameter: Calcium Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in calcium levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  16. Change From Baseline in Serum Chemistry Parameter: Chloride Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in chloride levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  17. Change From Baseline in Serum Chemistry Parameter: Creatine Kinase Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatine kinase levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  18. Change From Baseline in Serum Chemistry Parameter: Creatinine Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatinine levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  19. Change From Baseline in Serum Chemistry Parameter: Glucose Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in glucose levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  20. Change From Baseline in Serum Chemistry Parameter: Lipase Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in lipase levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  21. Change From Baseline in Serum Chemistry Parameter: Magnesium Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in magnesium levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  22. Change From Baseline in Serum Chemistry Parameter: Potassium Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in potassium levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  23. Change From Baseline in Serum Chemistry Parameter: Protein Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in protein levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  24. Change From Baseline in Serum Chemistry Parameter: Sodium Levels

    Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in sodium levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  25. Change From Baseline in Hematology Parameter: Basophil Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophil levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  26. Change From Baseline in Hematology Parameter: Basophils to Leukocytes Ratio Reported in Percentage of Cells

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  27. Change From Baseline in Hematology Parameter: Eosinophil Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  28. Change From Baseline in Hematology Parameter: Eosinophils to Leukocytes Ratio Reported in Percentage of Cells

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  29. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Concentration Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin concentration levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  30. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  31. Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  32. Change From Baseline in Hematology Parameter: Erythrocyte Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocyte levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  33. Change From Baseline in Hematology Parameter: Hematocrit Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hematocrit levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  34. Change From Baseline in Hematology Parameter: Hemoglobin Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hemoglobin levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  35. Change From Baseline in Hematology Parameter: Leukocyte Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in leukocyte levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  36. Change From Baseline in Hematology Parameter: Lymphocyte Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocyte levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  37. Change From Baseline in Hematology Parameter: Lymphocytes to Leukocytes Ratio Reported in Percentage of Cells

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  38. Change From Baseline in Hematology Parameter: Monocyte Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocyte levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  39. Change From Baseline in Hematology Parameter: Monocytes to Leukocytes Ratio Reported in Percentage of Cells

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  40. Change From Baseline in Hematology Parameter: Neutrophil Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophil levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  41. Change From Baseline in Hematology Parameter: Neutrophils to Leukocytes Ratio Reported in Percentage of Cells

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  42. Change From Baseline in Hematology Parameter: Platelet Levels

    Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in platelet levels is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  43. Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate

    ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in heart rate is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  44. Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval and QTc Interval

    ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in PR interval, QT interval, QRS duration and QTc interval is reported in this outcome measure.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  45. Number of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage

    Prior AEDs and Pressors are those medications that ended before the initiation of SAGE-547 infusion.

    Time frame: Up to Day 29

Secondary outcomes

  1. Number of Participants With Relapse - Re-Initiation of Third-Line Agent

    Relapse of participants is defined as successfully weaning from a continuous IV third-line agent but subsequent requirement of re-initiation of a third-line agent following conclusion of SAGE-547 treatment.

    Time frame: Up to Day 29

  2. Number of Participants With Treatment Response (Treatment Responders)

    A responder was defined as a participant for whom it was not required to re-initiate continuous IV third-line therapy for refractory seizure control during the administration of SAGE-547 at the maintenance dose (prior to SAGE-547 taper infusion).

    Time frame: Up to 96 hours

  3. Duration of Response

    Duration of response was defined as the time from the stop date/time of SAGE-547 maintenance to re-initiation of a third-line agent. If no re-initiation of a third-line agent was required, duration of response was not estimable and censored at Day 29 or death date, whichever occurred first. Kaplan-Meier method was used for the analysis.

    Time frame: Up to Day 29

  4. Maximum Plasma Concentration (Cmax) of SAGE-547

    Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose

  5. Time to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-547

    Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose

  6. Areas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast)

    Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose

  7. Area Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24)

    Time frame: Pre-dose (0 hours), 1, 2, 4, 8 and 24 hours post-dose

  8. Area Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96)

    Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose

  9. Average Plasma Concentration (Cav) of SAGE-547

    Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose

  10. Plasma Clearance (CL) of SAGE-547

    Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.

    Time frame: Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose

  11. Change From Baseline in Modified Rankin Scale (mRS-9Q) Scores

    The mRS-9Q is a commonly used scale to determine disability and functional dependence due to neurological insult such as a stroke. It is a shortened version consisting of 9 questions. The score was categorized on the scale of 0 to 5 (0 = No symptoms, 1 = No significant disability, able to carry out all usual activities, despite some symptoms, 2 = Slight disability, able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability, requires some help, but able to walk unassisted, 4 = Moderately severe disability, unable to attend to own bodily needs without assistance or unable to walk unassisted, and 5 = Severe disability, requires constant nursing care and attention, bedridden). Higher scores indicated worsening of symptoms.

    Time frame: Baseline (Screening) to Infusion at 49-72 hour, 73-96 hour; Extended follow-up at Day 8, 15, 22 and 29

  12. Change From Baseline in Clinical Global Impression: Severity Scale (CGI-S)

    The CGI-Severity (CGI-S) scale employs a 7-point Likert scale to assess the severity of participant's current illness state. Clinician responded to a question "Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?" on the following scores: 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, and 7 = Among the most extremely ill, where higher score = more affected.

    Time frame: Baseline (Screening), Extended follow-up at Days 8, 15, 22, and 29

  13. Clinical Global Impression: Improvement Scale (CGI-I) Scores

    The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse; where higher scores indicated worst outcomes. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.

    Time frame: Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  14. Change From Baseline in Glasgow Coma Scale (GCS) Scores

    The Glasgow Coma Scale is divided into three components which are scored separately: ocular response (assessment 1-4 points), motor response (assessment 1-6 points), verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total score that will range between a minimum of 3 points (which corresponds to a participant who does not open his/her eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a participant with open eyes, obeying orders and maintaining a consistent language). It has been considered that the GCS score between 15 and 13 points corresponds to a slight alteration of consciousness, a score of 12-9 points with moderate impairment and 8 points or less with a serious deterioration in level of consciousness.

    Time frame: Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  15. Change From Baseline in Richmond Agitation Sedation Scale (RASS) Score

    The RASS was an assessment of agitation and sedation in hospitalized participants, using a 10 point scale (ranged from -5 to +4), where, -5 = Unarousable, -4 = Deep sedation, -3 = Moderate sedation, -2 = Light sedation, -1 = Drowsy, 0 = Alert and calm, +1 = Restless, +2 = Agitated, +3 = Very agitated and +4 = Combative. Lower scores signify higher levels of sedation and higher scores signify heightened agitation. Participant in a calm and alert state would score a 0.

    Time frame: Baseline (Screening) to Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29

  16. Number of Participants Who Survived

    Survival time was defined as duration of survival from screening up to Day 29.

    Time frame: Up to Day 29

07

Results

Posted May 3, 2022

Participant flow

Participants took part in the study at 12 sites in United States from 21 March 2014 to 03 May 2015.

Participant flow — Overall Study
MilestoneSAGE-547 Standard DoseSAGE-547 High Dose
Started196
Completed145
Not completed51
Withdrew: Withdrew due to adverse event30
Withdrew: Participant died21

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs are defined as those that begin on or after initiation of the infusion of SAGE-547.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsSAGE-547 Standard DoseSAGE-547 High Dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)176
PrimaryChange From Baseline (CFB) in National Institutes of Health Stroke Scale (NIH-SS) Total Score

The National Institutes of Health Stroke Scale (NIH-SS) was used to examine the physical and neurological state of the participants. The NIH-SS is a 15-item assessment with measures of level of consciousness, visual gaze and vision loss, facial palsy, motor ability, ataxia, sensory ability, aphasia, dysarthria, and inattention. The total NIHSS score range is from 0 (normal) to 42 (severe impairment), with higher values indicating greater level of neurological impairment.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · score on a scale
Change From Baseline (CFB) in National Institutes of Health Stroke Scale (NIH-SS) Total Score
score on a scaleSAGE-547 Standard DoseSAGE-547 High Dose
Baseline34.2 ± 4.6933.0 ± 4.86
CFB at Infusion: 0-24 hours0.7 ± 2.300.3 ± 1.51
CFB at Infusion: 25-48 hours0.8 ± 3.47-1.5 ± 6.19
CFB at Infusion: 49-72 hours-2.2 ± 6.70-2.3 ± 4.63
CFB at Infusion: 73-96 hours-2.9 ± 8.08-5.5 ± 6.63
CFB at Infusion: 97-120 hours-5.6 ± 7.44-6.7 ± 7.20
CFB at Acute Follow-up: 121-144 hours-7.0 ± 8.75-10.8 ± 10.13
CFB at Acute Follow-up: 145-168 hours-7.5 ± 9.78-12.0 ± 8.76
CFB at Extended Follow-up: Day 8-9.0 ± 9.54-15.4 ± 11.82
CFB at Extended Follow-up: Day 15-16.8 ± 12.10-16.6 ± 13.30
CFB at Extended Follow-up: Day 22-15.1 ± 14.35-17.2 ± 14.55
CFB at Extended Follow-up: Day 29-16.7 ± 15.34-20.6 ± 13.09
PrimaryChange From Baseline in Vital Sign Parameter: Body Weight

Vital signs included weight, heart rate, blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), respiratory rate, temperature, oxygen saturation. CFB in body weight is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · kilograms (kg)
Change From Baseline in Vital Sign Parameter: Body Weight
kilograms (kg)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline78.263 ± 25.390581.667 ± 20.3141
CFB at Infusion: 0-24 hours0.253 ± 3.33210.250 ± 0.3987
CFB at Infusion: 25-48 hours1.095 ± 3.93921.083 ± 2.1424
CFB at Infusion: 49-72 hours1.444 ± 3.5787-0.933 ± 2.9561
CFB at Infusion: 73-96 hours1.517 ± 4.5509-0.033 ± 4.4275
CFB at Infusion: 97-120 hours0.688 ± 4.31481.567 ± 8.8672
CFB at Acute Follow-up: 121-144 hours-0.631 ± 6.37341.650 ± 12.6751
CFB at Acute Follow-up: 145-168 hours-0.930 ± 7.7080-5.100 ± 4.8298
CFB at Extended Follow-up: Day 80.436 ± 9.5258-1.720 ± 7.6392
CFB at Extended Follow-up: Day 15-0.708 ± 10.1362-6.100 ± 4.7589
CFB at Extended Follow-up: Day 220.644 ± 8.9288-3.420 ± 12.4474
CFB at Extended Follow-up: Day 29-6.130 ± 13.52430.108 ± 19.4907
PrimaryChange From Baseline in Vital Sign Parameter: Heart Rate

Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in heart rate is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended Follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · beats per minute (beats/min)
Change From Baseline in Vital Sign Parameter: Heart Rate
beats per minute (beats/min)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline89.3 ± 14.3381.8 ± 20.90
CFB at Infusion: 0-24 hours: Loading - Pre-Dose-2.3 ± 4.65-0.5 ± 2.12
CFB at Infusion: 0-24 hours: Loading - 15 minutes-0.7 ± 3.360.6 ± 1.52
CFB at Infusion: 0-24 hours: Loading - 30 minutes0.2 ± 5.26-2.0 ± 2.45
CFB at Infusion: 0-24 hours: Loading - 45 minutes-0.9 ± 3.98-3.6 ± 4.10
CFB at Infusion: 0-24 hours: 1 hour-1.3 ± 4.18-4.7 ± 7.26
CFB at Infusion: 0-24 hours: 2 hours-1.6 ± 4.92-0.5 ± 7.56
CFB at Infusion: 0-24 hours: 4 hours-0.6 ± 7.65-2.8 ± 8.52
CFB at Infusion: 0-24 hours: 8 hours-3.5 ± 9.87-10.7 ± 10.07
CFB at Infusion: 0-24 hours: 24 hours-2.2 ± 13.521.8 ± 7.11
CFB at Infusion: 25-48 hours: 48 hours1.9 ± 15.09-4.8 ± 8.04
CFB at Infusion: 49-72 hours: 72 hours5.4 ± 13.652.7 ± 12.42
CFB at Infusion: 73-96 hours: 96 hours6.8 ± 14.038.0 ± 14.38
CFB at Infusion: 97-120 hours: 120 hours12.9 ± 13.4310.7 ± 28.86
CFB at Acute Follow-up: 121-144 hours10.1 ± 13.1018.0 ± 23.33
CFB at Acute Follow-up: 145-168 hours10.9 ± 15.7714.8 ± 17.17
CFB at Extended Follow-up: Day 811.8 ± 12.695.6 ± 15.34
CFB at Extended Follow-up: Day 1512.8 ± 15.666.0 ± 12.63
CFB at Extended Follow-up: Day 2213.3 ± 11.9213.6 ± 27.88
CFB at Extended Follow-up: Day 299.5 ± 16.1911.2 ± 26.54
PrimaryChange From Baseline in Vital Sign Parameter: Blood Pressure - SBP and DBP

Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in SBP and DBP is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72: 72 hour;73-96: 96 hour;97-120:120 hour;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8,15,22 and 29
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Vital Sign Parameter: Blood Pressure - SBP and DBP
millimeters of mercury (mmHg)SAGE-547 Standard DoseSAGE-547 High Dose
SBP Baseline111.1 ± 14.55111.8 ± 7.46
SBP CFB at Infusion: 0-24 hours: Loading - Pre-Dose1.3 ± 13.2320.0 ± 28.28
SBP CFB at Infusion: 0-24 hours: Loading - 15 minutes-3.2 ± 8.365.0 ± 11.85
SBP CFB at Infusion: 0-24 hours: Loading - 30 minutes-4.3 ± 12.643.8 ± 11.12
SBP CFB at Infusion: 0-24 hours: Loading - 45 minutes-5.3 ± 12.55-9.4 ± 12.22
SBP CFB at Infusion: 0-24 hours: 1 hour-7.4 ± 11.96-6.8 ± 11.39
SBP CFB at Infusion: 0-24 hours: 2 hours-6.1 ± 15.96-5.7 ± 19.72
SBP CFB at Infusion: 0-24 hours: 4 hours-1.1 ± 14.40-1.7 ± 11.81
SBP CFB at Infusion: 0-24 hours: 8 hours-5.1 ± 18.55-1.3 ± 18.02
SBP CFB at Infusion: 0-24 hours: 24 hour-5.6 ± 19.265.7 ± 17.63
SBP CFB at Infusion: 25-48 hours: 48 hours-3.1 ± 21.492.5 ± 21.55
SBP CFB at Infusion: 49-72 hours: 72 hours-2.1 ± 27.723.0 ± 23.83
SBP CFB at Infusion: 73-96 hours: 96 hours6.2 ± 24.0611.8 ± 24.39
SBP CFB at Infusion: 97-120 hours: 120 hours-6.9 ± 22.13-1.8 ± 21.04
SBP CFB at Acute Follow-up: 121-144 hours-2.2 ± 18.6712.8 ± 21.58
SBP CFB at Acute Follow-up: 145-168 hours-0.2 ± 24.467.0 ± 25.93
SBP CFB at Extended Follow-up: Day 8-0.9 ± 21.125.0 ± 16.02
SBP CFB at Extended Follow-up: Day 158.9 ± 19.553.2 ± 11.52
SBP CFB at Extended Follow-up: Day 221.6 ± 27.607.0 ± 6.75
SBP CFB at Extended Follow-up: Day 292.0 ± 24.202.8 ± 19.77
DBP Baseline59.7 ± 8.5160.8 ± 10.69
DBP CFB at Infusion: 0-24 hours: Loading - Pre-Dose1.3 ± 10.537.5 ± 10.61
DBP CFB at Infusion: 0-24 hours: Loading - 15 minutes-2.1 ± 5.832.2 ± 4.15
DBP CFB at Infusion: 0-24 hours: Loading - 30 minutes-2.6 ± 10.383.6 ± 5.41
DBP CFB at Infusion: 0-24 hours: Loading - 45 minutes-3.3 ± 6.26-3.6 ± 7.33
DBP CFB at Infusion: 0-24 hours: 1 hour-3.4 ± 8.17-1.8 ± 3.25
DBP CFB at Infusion: 0-24 hours: 2 hours-2.8 ± 6.70-3.2 ± 9.56
DBP CFB at Infusion: 0-24 hours: 4 hours-1.7 ± 7.360.0 ± 8.67
DBP CFB at Infusion: 0-24 hours: 8 hours-2.5 ± 7.11-5.0 ± 12.17
DBP CFB at Infusion: 0-24 hours: 24 hours-2.9 ± 12.616.3 ± 24.99
DBP CFB at Infusion: 25-48 hours: 48 hours-2.9 ± 9.01-4.0 ± 7.87
DBP CFB at Infusion: 49-72 hours: 72 hours-1.2 ± 16.37-4.2 ± 5.42
DBP CFB at Infusion: 73-96 hours: 96 hours1.1 ± 12.093.3 ± 7.58
DBP CFB at Infusion: 97-120 hours: 120 hours-3.4 ± 12.651.0 ± 12.13
DBP CFB at Acute Follow-up: 121-144 hours-1.8 ± 11.536.6 ± 8.99
DBP CFB at Acute Follow-up: 145-168 hours0.8 ± 18.153.0 ± 18.59
DBP CFB at Extended Follow-up: Day 81.1 ± 12.401.0 ± 10.89
DBP CFB at Extended Follow-up: Day 157.9 ± 11.134.8 ± 6.22
DBP CFB at Extended Follow-up: Day 227.3 ± 14.6713.4 ± 11.72
DBP CFB at Extended Follow-up: Day 297.9 ± 11.0212.4 ± 22.78
PrimaryChange From Baseline in Vital Sign Parameter: Respiratory Rate

Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in respiratory rate is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · breaths per min (breaths/min)
Change From Baseline in Vital Sign Parameter: Respiratory Rate
breaths per min (breaths/min)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline17.4 ± 4.6613.4 ± 3.58
CFB at Infusion: 0-24 hours: Loading - Pre-Dose0.3 ± 2.75-2.0 ± 1.41
CFB at Infusion: 0-24 hours: Loading - 15 minutes0.2 ± 2.39-0.6 ± 0.89
CFB at Infusion: 0-24 hours: Loading - 30 minutes-0.3 ± 3.05-1.0 ± 1.41
CFB at Infusion: 0-24 hours: Loading - 45 minutes-0.3 ± 2.641.0 ± 2.65
CFB at Infusion: 0-24 hours: 1 hour0.2 ± 2.240.2 ± 1.47
CFB at Infusion: 0-24 hours: 2 hours1.1 ± 2.780.8 ± 1.33
CFB at Infusion: 0-24 hours: 4 hours0.6 ± 1.98-0.2 ± 1.33
CFB at Infusion: 0-24 hours: 8 hours-0.5 ± 2.14-0.3 ± 1.86
CFB at Infusion: 0-24 hours: 24 hours0.3 ± 4.080.7 ± 1.51
CFB at Infusion: 25-48 hours: 48 hours-0.1 ± 3.21-0.8 ± 3.66
CFB at Infusion: 49-72 hours: 72 hours1.6 ± 3.651.0 ± 6.96
CFB at Infusion: 73-96 hours: 96 hours4.7 ± 6.871.2 ± 6.97
CFB at Infusion: 97-120 hours: 120 hours2.5 ± 5.621.0 ± 4.90
CFB at Acute Follow-up: 121-144 hours3.2 ± 4.251.4 ± 5.77
CFB at Acute Follow-up: 145-168 hours4.2 ± 6.086.0 ± 6.32
CFB at Extended Follow-up: Day 84.3 ± 5.940.6 ± 3.05
CFB at Extended Follow-up: Day 153.7 ± 5.875.0 ± 6.40
CFB at Extended Follow-up: Day 224.9 ± 4.323.0 ± 6.00
CFB at Extended Follow-up: Day 293.5 ± 6.355.6 ± 11.28
PrimaryChange From Baseline in Vital Sign Parameter: Body Temperature

Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in body temperature is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · degrees Fahrenheit (F)
Change From Baseline in Vital Sign Parameter: Body Temperature
degrees Fahrenheit (F)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline99.21 ± 1.19598.98 ± 2.312
CFB at Infusion: 0-24 hours: Loading - Pre-Dose-0.80 ± 0.883-0.30 ± 0.707
CFB at Infusion: 0-24 hours: Loading - 15 minutes-0.38 ± 0.471-0.04 ± 0.329
CFB at Infusion: 0-24 hours: Loading - 30 minutes-0.54 ± 0.628-0.14 ± 0.371
CFB at Infusion: 0-24 hours: Loading - 45 minutes-0.58 ± 0.662-0.32 ± 0.432
CFB at Infusion: 0-24 hours: 1 hour-0.51 ± 0.614-0.55 ± 0.468
CFB at Infusion: 0-24 hours: 2 hours-0.44 ± 0.902-0.48 ± 0.407
CFB at Infusion: 0-24 hours: 4 hours-0.17 ± 1.269-0.47 ± 0.596
CFB at Infusion: 0-24 hours: 8 hours-0.74 ± 1.361-0.52 ± 0.985
CFB at Infusion: 0-24 hours: 24 hours-0.20 ± 1.7040.20 ± 1.474
CFB at Infusion: 25-48 hours: 48 hours-0.51 ± 1.467-0.47 ± 1.335
CFB at Infusion: 49-72 hours: 72 hours-0.53 ± 1.522-0.47 ± 1.296
CFB at Infusion: 73-96 hour: 96 hours-0.32 ± 1.263-0.62 ± 1.283
CFB at Infusion: 97-120 hours: 120 hours-0.14 ± 1.230-0.92 ± 1.514
CFB at Acute Follow-up: 121-144 hours0.06 ± 1.360-0.16 ± 1.450
CFB at Acute Follow-up: 145-168 hours-0.29 ± 1.896-0.20 ± 0.652
CFB at Extended Follow-up: Day 80.03 ± 1.010-0.46 ± 0.684
CFB at Extended Follow-up: Day 15-0.44 ± 1.852-0.42 ± 0.740
CFB at Extended Follow-up: Day 22-0.62 ± 1.834-0.96 ± 1.790
CFB at Extended Follow-up: Day 29-0.69 ± 1.515-1.20 ± 2.164
PrimaryChange From Baseline in Vital Sign Parameter: Oxygen Saturation

Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. Oxygen saturation is a measure of how much hemoglobin is currently bound to oxygen compared to how much hemoglobin remains unbound. CFB in oxygen saturation is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · percentage of oxygen saturation
Change From Baseline in Vital Sign Parameter: Oxygen Saturation
percentage of oxygen saturationSAGE-547 Standard DoseSAGE-547 High Dose
Baseline98.8 ± 2.2698.6 ± 1.67
CFB at Infusion: 0-24 hours: Loading - Pre-Dose0.0 ± 0.000.5 ± 0.71
CFB at Infusion: 0-24 hours: Loading - 15 minutes0.0 ± 0.330.2 ± 0.45
CFB at Infusion: 0-24 hours: Loading - 30 minutes-0.3 ± 1.450.4 ± 1.52
CFB at Infusion: 0-24 hours: Loading - 45 minutes-0.2 ± 1.080.2 ± 1.92
CFB at Infusion: 0-24 hours: 1 hour-0.5 ± 2.480.0 ± 1.55
CFB at Infusion: 0-24 hours: 2 hours0.1 ± 1.10-1.3 ± 4.76
CFB at Infusion: 0-24 hours: 4 hours-0.2 ± 0.691.2 ± 1.33
CFB at Infusion: 0-24 hours: 8 hours-0.1 ± 1.451.0 ± 0.89
CFB at Infusion: 0-24 hours: 24 hours0.0 ± 1.15-0.7 ± 1.75
CFB at Infusion: 25-48 hours: 48 hours-0.6 ± 2.750.8 ± 0.98
CFB at Infusion: 49-72 hours: 72 hours-0.1 ± 2.010.3 ± 1.97
CFB at Infusion: 73-96 hours: 96 hours-0.3 ± 2.95-0.8 ± 2.48
CFB at Infusion: 97-120 hours: 120 hours-0.5 ± 2.62-1.3 ± 2.34
CFB at Acute Follow-up: 121-144 hours0.1 ± 2.110.0 ± 1.58
CFB at Acute Follow-up: 145-168 hours-0.3 ± 2.31-0.8 ± 2.86
CFB at Extended Follow-up: Day 8-0.5 ± 2.58-0.2 ± 1.64
CFB at Extended Follow-up: Day 15-1.1 ± 2.900.4 ± 0.55
CFB at Extended Follow-up: Day 22-6.9 ± 22.320.6 ± 1.52
CFB at Extended Follow-up: Day 29-1.3 ± 3.54-1.2 ± 1.30
PrimaryChange From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in alanine aminotransferase levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · international units per liter (IU/L)
Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase Levels
international units per liter (IU/L)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline48.7 ± 82.9240.0 ± 32.47
CFB at Infusion: 0-24 hours8.2 ± 23.9617.0 ± 42.85
CFB at Infusion: 25-48 hours11.0 ± 39.6239.3 ± 69.34
CFB at Infusion: 49-72 hours5.6 ± 42.7736.5 ± 48.02
CFB at Infusion: 73-96 hours1.9 ± 50.9784.0 ± 124.28
CFB at Infusion: 97-120 hours4.3 ± 64.93233.3 ± 475.33
CFB at Acute Follow-up: 121-144 hours4.6 ± 75.63109.5 ± 222.80
CFB at Acute Follow-up: 145-168 hours5.6 ± 72.2548.5 ± 107.03
CFB at Extended Follow-up: Day 84.9 ± 69.890.4 ± 29.80
CFB at Extended Follow-up: Day 15-4.5 ± 85.0632.2 ± 47.21
CFB at Extended Follow-up: Day 22-3.6 ± 46.9144.0 ± 65.01
CFB at Extended Follow-up: Day 2961.2 ± 309.38374.0 ± 404.96
PrimaryChange From Baseline in Serum Chemistry Parameter: Albumin Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in albumin levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · grams per liter (g/L)
Change From Baseline in Serum Chemistry Parameter: Albumin Levels
grams per liter (g/L)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline26.7 ± 4.8721.3 ± 3.67
CFB at Infusion: 0-24 hours-0.3 ± 1.75-1.3 ± 3.33
CFB at Infusion: 25-48 hours-0.5 ± 1.84-0.7 ± 7.17
CFB at Infusion: 49-72 hours-0.2 ± 2.320.7 ± 5.28
CFB at Infusion: 73-96 hours0.1 ± 2.263.8 ± 8.54
CFB at Infusion: 97-120 hours-0.1 ± 2.455.0 ± 6.60
CFB at Acute Follow-up: 121-144 hours0.3 ± 2.825.3 ± 8.71
CFB at Acute Follow-up: 145-168 hours0.6 ± 3.617.5 ± 8.96
CFB at Extended Follow-up: Day 81.2 ± 4.349.2 ± 9.44
CFB at Extended Follow-up: Day 152.8 ± 6.4510.2 ± 6.22
CFB at Extended Follow-up: Day 225.7 ± 7.469.5 ± 1.73
CFB at Extended Follow-up: Day 294.8 ± 7.9112.3 ± 4.04
PrimaryChange From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in aspartate aminotransferase levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · IU/L
Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase Levels
IU/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline43.8 ± 50.4144.8 ± 35.87
CFB at Infusion: 0-24 hours0.9 ± 43.2418.3 ± 31.42
CFB at Infusion: 25-48 hours7.5 ± 43.2832.7 ± 30.66
CFB at Infusion: 49-72 hours-0.8 ± 40.4024.5 ± 24.99
CFB at Infusion: 73-96 hours2.4 ± 39.23146.7 ± 328.43
CFB at Infusion: 97-120 hours8.7 ± 39.62854.5 ± 2056.68
CFB at Acute Follow-up: 121-144 hours11.8 ± 35.16440.3 ± 1067.48
CFB at Acute Follow-up: 145-168 hours12.6 ± 29.27264.7 ± 654.96
CFB at Extended Follow-up: Day 810.8 ± 34.72-5.2 ± 16.63
CFB at Extended Follow-up: Day 152.9 ± 33.3329.0 ± 48.93
CFB at Extended Follow-up: Day 2215.8 ± 68.7325.0 ± 55.47
CFB at Extended Follow-up: Day 2924.9 ± 121.921888.0 ± 3115.96
PrimaryChange From Baseline in Serum Chemistry Parameter: Bicarbonate Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bicarbonate levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Serum Chemistry Parameter: Bicarbonate Levels
millimoles per liter (mmol/L)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline22.29 ± 5.24724.52 ± 4.481
CFB at Infusion: 0-24 hours0.29 ± 2.077-0.85 ± 2.411
CFB at Infusion: 25-48 hours0.68 ± 3.607-0.90 ± 2.205
CFB at Infusion: 49-72 hours1.12 ± 3.252-0.98 ± 3.060
CFB at Infusion: 73-96 hours1.10 ± 3.258-0.20 ± 3.200
CFB at Infusion: 97-120 hours1.42 ± 4.187-0.83 ± 4.262
CFB at Acute Follow-up: 121-144 hours1.68 ± 4.834-1.75 ± 5.511
CFB at Acute Follow-up: 145-168 hours1.85 ± 5.119-2.15 ± 5.829
CFB at Extended Follow-up: Day 81.27 ± 5.397-0.06 ± 4.463
CFB at Extended Follow-up: Day 150.95 ± 5.3091.14 ± 6.527
CFB at Extended Follow-up: Day 221.45 ± 6.2391.56 ± 5.447
CFB at Extended Follow-up: Day 292.59 ± 6.4320.25 ± 6.850
PrimaryChange From Baseline in Serum Chemistry Parameter: Bilirubin Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bilirubin levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · micromoles per liter (μmol/L)
Change From Baseline in Serum Chemistry Parameter: Bilirubin Levels
micromoles per liter (μmol/L)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline15.3900 ± 37.320866.8400 ± 7.41438
CFB at Infusion: 0-24 hours-2.8165 ± 7.328630.8550 ± 2.35707
CFB at Infusion: 25-48 hours-3.0176 ± 8.688450.0000 ± 5.72275
CFB at Infusion: 49-72 hours-1.0688 ± 3.11420-1.4250 ± 6.15758
CFB at Infusion: 73-96 hours1.9237 ± 5.14423-0.8550 ± 5.59356
CFB at Infusion: 97-120 hours1.3680 ± 6.272960.0000 ± 7.33508
CFB at Acute Follow-up: 121-144 hours1.4657 ± 6.566770.5700 ± 9.34522
CFB at Acute Follow-up: 145-168 hours3.9086 ± 10.203473.7050 ± 14.56682
CFB at Extended Follow-up: Day 87.2064 ± 18.06184-2.0520 ± 7.49284
CFB at Extended Follow-up: Day 157.6292 ± 25.00165-2.3940 ± 7.31512
CFB at Extended Follow-up: Day 224.4197 ± 18.18369-0.4275 ± 5.10619
CFB at Extended Follow-up: Day 2926.5050 ± 69.147602.2800 ± 1.97454
PrimaryChange From Baseline in Serum Chemistry Parameter: Blood Urea Nitrogen Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in blood urea nitrogen levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · mmol/L
Change From Baseline in Serum Chemistry Parameter: Blood Urea Nitrogen Levels
mmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline4.7162 ± 2.049354.9980 ± 1.62817
CFB at Infusion: 0-24 hours0.5752 ± 0.90926-0.1785 ± 0.58661
CFB at Infusion: 25-48 hours1.2025 ± 1.55708-0.7140 ± 1.17322
CFB at Infusion: 49-72 hours1.3090 ± 1.79547-0.8925 ± 1.16778
CFB at Infusion: 73-96 hours1.6462 ± 2.02001-0.1785 ± 1.99090
CFB at Infusion: 97-120 hours2.0160 ± 2.229250.6545 ± 2.82384
CFB at Acute Follow-up: 121-144 hours2.1000 ± 2.371042.0825 ± 2.79663
CFB at Acute Follow-up: 145-168 hours2.1197 ± 2.641061.9040 ± 2.79890
CFB at Extended Follow-up: Day 81.8743 ± 2.745271.1424 ± 2.55448
CFB at Extended Follow-up: Day 151.5396 ± 2.645070.0714 ± 2.14794
CFB at Extended Follow-up: Day 222.0145 ± 5.10015-0.0714 ± 3.73914
CFB at Extended Follow-up: Day 291.0115 ± 3.403291.3388 ± 0.79160
PrimaryChange From Baseline in Serum Chemistry Parameter: Calcium Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in calcium levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · mmol/L
Change From Baseline in Serum Chemistry Parameter: Calcium Levels
mmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline0.2037 ± 0.011530.1950 ± 0.02074
CFB at Infusion: 0-24 hours0.0015 ± 0.007330.0021 ± 0.00732
CFB at Infusion: 25-48 hours0.0036 ± 0.009840.0017 ± 0.01765
CFB at Infusion: 49-72 hours0.0056 ± 0.015210.0067 ± 0.02149
CFB at Infusion: 73-96 hours0.0078 ± 0.015220.0079 ± 0.02947
CFB at Infusion: 97-120 hours0.0084 ± 0.017140.0117 ± 0.02493
CFB at Acute Follow-up: 121-144 hours0.0071 ± 0.017030.0125 ± 0.02766
CFB at Acute Follow-up: 145-168 hours0.0100 ± 0.011800.0092 ± 0.02553
CFB at Extended Follow-up: Day 80.0114 ± 0.010160.0170 ± 0.01866
CFB at Extended Follow-up: Day 150.0172 ± 0.018730.0170 ± 0.01681
CFB at Extended Follow-up: Day 220.0202 ± 0.030170.0219 ± 0.00688
CFB at Extended Follow-up: Day 290.0121 ± 0.027490.0300 ± 0.00750
PrimaryChange From Baseline in Serum Chemistry Parameter: Chloride Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in chloride levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · mmol/L
Change From Baseline in Serum Chemistry Parameter: Chloride Levels
mmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline110.0 ± 6.21109.7 ± 3.72
CFB at Infusion: 0-24 hours0.2 ± 2.82-3.5 ± 3.56
CFB at Infusion: 25-48 hours-0.6 ± 3.32-0.5 ± 5.17
CFB at Infusion: 49-72 hours-1.1 ± 3.740.5 ± 6.60
CFB at Infusion: 73-96 hours-1.6 ± 4.22-0.3 ± 4.63
CFB at Infusion: 97-120 hours-2.9 ± 5.07-2.7 ± 2.73
CFB at Acute Follow-up: 121-144 hours-2.5 ± 6.96-1.8 ± 4.92
CFB at Acute Follow-up: 145-168 hours-4.1 ± 7.36-1.2 ± 3.97
CFB at Extended Follow-up: Day 8-4.0 ± 7.32-3.4 ± 5.55
CFB at Extended Follow-up: Day 15-5.9 ± 9.02-4.6 ± 12.12
CFB at Extended Follow-up: Day 22-4.1 ± 8.63-10.8 ± 5.81
CFB at Extended Follow-up: Day 29-7.2 ± 6.73-11.0 ± 4.69
PrimaryChange From Baseline in Serum Chemistry Parameter: Creatine Kinase Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatine kinase levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · IU/L
Change From Baseline in Serum Chemistry Parameter: Creatine Kinase Levels
IU/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline164.6 ± 297.581056.4 ± 1476.88
CFB at Infusion: 0-24 hours-5.4 ± 99.2980.0 ± 343.91
CFB at Infusion: 25-48 hours-41.5 ± 204.71-77.0 ± 226.45
CFB at Infusion: 49-72 hours-52.8 ± 240.39-35.2 ± 375.74
CFB at Infusion: 73-96 hours-54.8 ± 250.36187.8 ± 428.72
CFB at Infusion: 97-120 hours-69.4 ± 267.621034.6 ± 2557.56
CFB at Acute Follow-up: 121-144 hours-94.9 ± 280.01864.2 ± 2487.87
CFB at Acute Follow-up: 145-168 hours-43.8 ± 269.891462.6 ± 3745.02
CFB at Extended Follow-up: Day 8-39.5 ± 286.63-67.0 ± 684.14
CFB at Extended Follow-up: Day 15-70.5 ± 293.08-294.5 ± 520.14
CFB at Extended Follow-up: Day 22-108.7 ± 284.99-245.5 ± 217.08
CFB at Extended Follow-up: Day 295.9 ± 51.57-356.7 ± 596.58
PrimaryChange From Baseline in Serum Chemistry Parameter: Creatinine Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatinine levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · μmol/L
Change From Baseline in Serum Chemistry Parameter: Creatinine Levels
μmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline61.8335 ± 38.3513866.1527 ± 26.85624
CFB at Infusion: 0-24 hours3.5851 ± 21.18016-4.2727 ± 3.96981
CFB at Infusion: 25-48 hours-0.3257 ± 17.04796-2.7993 ± 9.97654
CFB at Infusion: 49-72 hours-5.4513 ± 17.92081-5.1567 ± 13.15250
CFB at Infusion: 73-96 hours-9.0364 ± 24.693532.6520 ± 34.21891
CFB at Infusion: 97-120 hours-11.1800 ± 28.1979715.1753 ± 34.57069
CFB at Acute Follow-up: 121-144 hours-10.4000 ± 30.5116632.4133 ± 73.92834
CFB at Acute Follow-up: 145-168 hours-6.5748 ± 39.9322437.8647 ± 103.07822
CFB at Extended Follow-up: Day 8-9.8345 ± 34.60628-1.5912 ± 12.81648
CFB at Extended Follow-up: Day 15-7.1825 ± 30.96420-3.3592 ± 13.75749
CFB at Extended Follow-up: Day 22-4.6726 ± 33.58740-11.6688 ± 33.48365
CFB at Extended Follow-up: Day 2911.7867 ± 78.663210.0000 ± 23.06320
PrimaryChange From Baseline in Serum Chemistry Parameter: Glucose Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in glucose levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · mmol/L
Change From Baseline in Serum Chemistry Parameter: Glucose Levels
mmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline7.0731 ± 1.609407.1238 ± 2.48860
CFB at Infusion: 0-24 hours0.7247 ± 1.218472.5905 ± 3.70841
CFB at Infusion: 25-48 hours0.2542 ± 1.754140.6661 ± 1.44582
CFB at Infusion: 49-72 hours1.0886 ± 2.999121.4155 ± 3.15690
CFB at Infusion: 73-96 hours0.0956 ± 1.980210.2405 ± 1.85063
CFB at Infusion: 97-120 hours0.4539 ± 1.531470.2035 ± 2.89966
CFB at Acute Follow-up: 121-144 hours0.1437 ± 2.207440.5644 ± 1.44173
CFB at Acute Follow-up: 145-168 hours-0.1457 ± 1.83254-0.2683 ± 1.26456
CFB at Extended Follow-up: Day 8-0.1596 ± 1.85981-1.4766 ± 2.48794
CFB at Extended Follow-up: Day 15-0.4788 ± 1.91895-0.0999 ± 3.18721
CFB at Extended Follow-up: Day 22-0.4084 ± 2.50478-0.1554 ± 4.07581
CFB at Extended Follow-up: Day 29-1.1565 ± 1.79106-1.5959 ± 2.23900
PrimaryChange From Baseline in Serum Chemistry Parameter: Lipase Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in lipase levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · IU/L
Change From Baseline in Serum Chemistry Parameter: Lipase Levels
IU/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline69.7 ± 108.5648.3 ± 55.19
CFB at Infusion: 0-24 hours-13.4 ± 43.773.3 ± 3.21
CFB at Infusion: 25-48 hours-7.5 ± 34.959.3 ± 13.58
CFB at Infusion: 49-72 hours-14.4 ± 36.770.0 ± 1.73
CFB at Infusion: 73-96 hours-22.4 ± 64.0118.0 ± 25.36
CFB at Infusion: 97-120 hours-20.5 ± 63.33-6.7 ± 22.74
CFB at Acute Follow-up: 121-144 hours-20.3 ± 91.54-10.7 ± 37.87
CFB at Acute Follow-up: 145-168 hours-11.7 ± 99.609.3 ± 16.92
CFB at Extended Follow-up: Day 8-3.7 ± 100.7837.0 ± 28.16
CFB at Extended Follow-up: Day 1524.7 ± 44.4219.7 ± 100.17
CFB at Extended Follow-up: Day 2214.1 ± 38.25-15.0 ± 84.85
CFB at Extended Follow-up: Day 29-8.3 ± 35.420.0 ± 31.00
PrimaryChange From Baseline in Serum Chemistry Parameter: Magnesium Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in magnesium levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · mmol/L
Change From Baseline in Serum Chemistry Parameter: Magnesium Levels
mmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline0.8969 ± 0.195460.8607 ± 0.14418
CFB at Infusion: 0-24 hours-0.0219 ± 0.11853-0.0441 ± 0.06638
CFB at Infusion: 25-48 hours-0.0194 ± 0.14406-0.0319 ± 0.11737
CFB at Infusion: 49-72 hours-0.0430 ± 0.11666-0.0167 ± 0.12869
CFB at Infusion: 73-96 hours-0.0374 ± 0.172680.0304 ± 0.16521
CFB at Infusion: 97-120 hours-0.0151 ± 0.223580.0754 ± 0.10859
CFB at Acute Follow-up: 121-144 hours-0.0348 ± 0.187420.0534 ± 0.13315
CFB at Acute Follow-up: 145-168 hours-0.0151 ± 0.214980.0519 ± 0.15865
CFB at Extended Follow-up: Day 8-0.0435 ± 0.15736-0.0811 ± 0.16860
CFB at Extended Follow-up: Day 15-0.0645 ± 0.15320-0.0494 ± 0.09381
CFB at Extended Follow-up: Day 22-0.0564 ± 0.19263-0.1264 ± 0.15097
CFB at Extended Follow-up: Day 29-0.1484 ± 0.28794-0.0608 ± 0.08902
PrimaryChange From Baseline in Serum Chemistry Parameter: Potassium Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in potassium levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · mmol/L
Change From Baseline in Serum Chemistry Parameter: Potassium Levels
mmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline3.76 ± 0.4393.87 ± 0.301
CFB at Infusion: 0-24 hours0.01 ± 0.515-0.03 ± 0.242
CFB at Infusion: 25-48 hours0.15 ± 0.717-0.10 ± 0.329
CFB at Infusion: 49-72 hours0.17 ± 0.788-0.37 ± 1.117
CFB at Infusion: 73-96 hours0.05 ± 0.6510.22 ± 0.601
CFB at Infusion: 97-120 hours0.00 ± 0.4460.35 ± 0.497
CFB at Acute Follow-up: 121-144 hours-0.02 ± 0.5420.37 ± 0.582
CFB at Acute Follow-up: 145-168 hours-0.06 ± 0.5780.75 ± 0.946
CFB at Extended Follow-up: Day 80.07 ± 0.5850.10 ± 0.255
CFB at Extended Follow-up: Day 150.04 ± 0.7340.42 ± 0.657
CFB at Extended Follow-up: Day 220.12 ± 0.6540.32 ± 0.683
CFB at Extended Follow-up: Day 290.21 ± 0.4420.38 ± 0.741
PrimaryChange From Baseline in Serum Chemistry Parameter: Protein Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in protein levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · g/L
Change From Baseline in Serum Chemistry Parameter: Protein Levels
g/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline56.5 ± 9.9152.2 ± 7.52
CFB at Infusion: 0-24 hours0.4 ± 1.711.0 ± 5.51
CFB at Infusion: 25-48 hours1.1 ± 2.341.5 ± 5.92
CFB at Infusion: 49-72 hours1.3 ± 4.084.0 ± 6.69
CFB at Infusion: 73-96 hours2.5 ± 4.106.5 ± 5.99
CFB at Infusion: 97-120 hours2.8 ± 2.968.8 ± 7.41
CFB at Acute Follow-up: 121-144 hours2.5 ± 5.056.3 ± 5.89
CFB at Acute Follow-up: 145-168 hours4.1 ± 4.877.5 ± 5.05
CFB at Extended Follow-up: Day 84.3 ± 5.065.6 ± 5.68
CFB at Extended Follow-up: Day 155.9 ± 9.2111.0 ± 6.44
CFB at Extended Follow-up: Day 226.7 ± 10.1816.5 ± 8.19
CFB at Extended Follow-up: Day 297.1 ± 11.5620.0 ± 7.21
PrimaryChange From Baseline in Serum Chemistry Parameter: Sodium Levels

Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in sodium levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · mmol/L
Change From Baseline in Serum Chemistry Parameter: Sodium Levels
mmol/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline140.6 ± 4.84141.7 ± 4.84
CFB at Infusion: 0-24 hours0.1 ± 2.87-3.8 ± 4.12
CFB at Infusion: 25-48 hours0.7 ± 4.310.3 ± 5.72
CFB at Infusion: 49-72 hours0.4 ± 3.881.7 ± 6.19
CFB at Infusion: 73-96 hours0.4 ± 3.501.5 ± 3.94
CFB at Infusion: 97-120 hours0.0 ± 4.80-0.5 ± 4.04
CFB at Acute Follow-up: 121-144 hours-0.3 ± 5.12-1.0 ± 4.60
CFB at Acute Follow-up: 145-168 hours-1.2 ± 5.640.2 ± 5.85
CFB at Extended Follow-up: Day 8-1.8 ± 5.650.0 ± 5.79
CFB at Extended Follow-up: Day 15-2.8 ± 5.51-0.4 ± 7.64
CFB at Extended Follow-up: Day 220.0 ± 5.53-3.2 ± 4.32
CFB at Extended Follow-up: Day 29-1.8 ± 6.34-4.5 ± 1.29
PrimaryChange From Baseline in Hematology Parameter: Basophil Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophil levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^3 cells per microliter(10^3 cells/uL)
Change From Baseline in Hematology Parameter: Basophil Levels
10^3 cells per microliter(10^3 cells/uL)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline0.031 ± 0.05090.037 ± 0.0321
CFB at Infusion: 0-24 hours0.013 ± 0.03080.003 ± 0.0058
CFB at Infusion: 25-48 hours-0.008 ± 0.0319-0.023 ± 0.0321
CFB at Infusion: 49-72 hours0.009 ± 0.0230-0.007 ± 0.0208
CFB at Infusion: 73-96 hours0.013 ± 0.0433-0.013 ± 0.0115
CFB at Infusion: 97-120 hours0.004 ± 0.0662-0.010 ± 0.0141
CFB at Acute Follow-up: 121-144 hours0.033 ± 0.03690.087 ± 0.1848
CFB at Acute Follow-up: 145-168 hours0.006 ± 0.0669-0.017 ± 0.0153
CFB at Extended Follow-up: Day 80.014 ± 0.0745-0.017 ± 0.0153
CFB at Extended Follow-up: Day 150.031 ± 0.03660.040 ± 0.0849
CFB at Extended Follow-up: Day 220.020 ± 0.02160.000
CFB at Extended Follow-up: Day 290.017 ± 0.0288-0.005 ± 0.0071
PrimaryChange From Baseline in Hematology Parameter: Basophils to Leukocytes Ratio Reported in Percentage of Cells

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · percentage of cells
Change From Baseline in Hematology Parameter: Basophils to Leukocytes Ratio Reported in Percentage of Cells
percentage of cellsSAGE-547 Standard DoseSAGE-547 High Dose
Baseline0.50 ± 0.7070.00 ± 0.000
CFB at Infusion: 0-24 hours0.000.00
CFB at Infusion: 25-48 hours0.00 ± 0.0001.00
CFB at Infusion: 49-72 hours0.00 ± 0.0000.00
CFB at Infusion: 73-96 hours0.50 ± 0.7071.00
CFB at Infusion: 97-120 hours0.00 ± 0.0001.00
CFB at Acute Follow-up: 121-144 hours0.00 ± 0.0000.00
CFB at Acute Follow-up: 145-168 hours0.00 ± 0.0000.00
CFB at Extended Follow-up: Day 80.00 ± 0.000—
CFB at Extended Follow-up: Day 15-0.50 ± 0.707—
CFB at Extended Follow-up: Day 220.50 ± 0.7070.00
CFB at Extended Follow-up: Day 290.00 ± 0.000—
PrimaryChange From Baseline in Hematology Parameter: Eosinophil Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^3 cells/uL
Change From Baseline in Hematology Parameter: Eosinophil Levels
10^3 cells/uLSAGE-547 Standard DoseSAGE-547 High Dose
Baseline0.3364 ± 0.427110.7433 ± 0.20108
CFB at Infusion: 0-24 hours0.0580 ± 0.17813-0.2700 ± 0.24269
CFB at Infusion: 25-48 hours0.0660 ± 0.23538-0.2333 ± 0.45654
CFB at Infusion: 49-72 hours-0.0911 ± 0.35069-0.6467 ± 0.14189
CFB at Infusion: 73-96 hours-0.0811 ± 0.36381-0.5867 ± 0.07095
CFB at Infusion: 97-120 hours-0.1878 ± 0.45535-0.4200 ± 0.41940
CFB at Acute Follow-up: 121-144 hours-0.2211 ± 0.44552-0.5567 ± 0.16258
CFB at Acute Follow-up: 145-168 hours-0.1643 ± 0.42177-0.5567 ± 0.17898
CFB at Extended Follow-up: Day 8-0.1056 ± 0.40423-0.5400 ± 0.17776
CFB at Extended Follow-up: Day 15-0.0078 ± 0.337740.0100 ± 0.26870
CFB at Extended Follow-up: Day 22-0.0543 ± 0.42496-0.3000
CFB at Extended Follow-up: Day 29-0.0229 ± 0.39982-0.5650 ± 0.33234
PrimaryChange From Baseline in Hematology Parameter: Eosinophils to Leukocytes Ratio Reported in Percentage of Cells

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · percentage of cells
Change From Baseline in Hematology Parameter: Eosinophils to Leukocytes Ratio Reported in Percentage of Cells
percentage of cellsSAGE-547 Standard DoseSAGE-547 High Dose
Baseline3.00 ± 0.0003.00 ± 0.000
CFB at Infusion: 0-24 hours5.00-2.00
CFB at Infusion: 25-48 hours0.50 ± 0.7070.00
CFB at Infusion: 49-72 hours-0.50 ± 2.1210.00
CFB at Infusion: 73-96 hours0.50 ± 0.707-2.00
CFB at Infusion: 97-120 hours-1.00 ± 0.000-2.00
CFB at Acute Follow-up: 121-144 hours-1.50 ± 0.707-3.00
CFB at Acute Follow-up: 145-168 hours-2.00 ± 1.414-3.00
CFB at Extended Follow-up: Day 80.50 ± 2.121—
CFB at Extended Follow-up: Day 152.00 ± 1.414—
CFB at Extended Follow-up: Day 221.00 ± 2.828-1.00
CFB at Extended Follow-up: Day 291.50 ± 0.707—
PrimaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Concentration Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin concentration levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · g/L
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Concentration Levels
g/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline328.4 ± 12.54322.6 ± 12.54
CFB at Infusion: 0-24 hours-1.2 ± 12.521.0 ± 5.66
CFB at Infusion: 25-48 hours-4.7 ± 10.4310.4 ± 12.18
CFB at Infusion: 49-72 hours-3.4 ± 7.885.4 ± 6.19
CFB at Infusion: 73-96 hours-3.6 ± 10.003.6 ± 6.35
CFB at Infusion: 97-120 hours-4.1 ± 9.331.8 ± 3.03
CFB at Acute Follow-up: 121-144 hours-6.1 ± 10.65-0.4 ± 2.61
CFB at Acute Follow-up: 145-168 hours-7.6 ± 10.440.4 ± 5.50
CFB at Extended Follow-up: Day 8-7.7 ± 11.07-2.3 ± 9.54
CFB at Extended Follow-up: Day 15-5.5 ± 14.28-0.5 ± 13.77
CFB at Extended Follow-up: Day 22-6.9 ± 18.4011.5 ± 32.25
CFB at Extended Follow-up: Day 29-4.6 ± 16.10-9.3 ± 7.50
PrimaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · femtomoles (fmol)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Levels
femtomoles (fmol)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline1.8611 ± 0.175641.8335 ± 0.09869
CFB at Infusion: 0-24 hours0.0110 ± 0.04180-0.0149 ± 0.02996
CFB at Infusion: 25-48 hours-0.0134 ± 0.036030.0261 ± 0.09580
CFB at Infusion: 49-72 hours-0.0097 ± 0.037190.0074 ± 0.03911
CFB at Infusion: 73-96 hours-0.0107 ± 0.04378-0.0099 ± 0.02177
CFB at Infusion: 97-120 hours-0.0164 ± 0.040340.0112 ± 0.03147
CFB at Acute Follow-up: 121-144 hours-0.0194 ± 0.036840.0099 ± 0.03582
CFB at Acute Follow-up: 145-168 hours-0.0112 ± 0.047630.0161 ± 0.03662
CFB at Extended Follow-up: Day 8-0.0058 ± 0.044910.0155 ± 0.04927
CFB at Extended Follow-up: Day 15-0.0087 ± 0.091820.0310 ± 0.07868
CFB at Extended Follow-up: Day 22-0.0306 ± 0.140550.0729 ± 0.14436
CFB at Extended Follow-up: Day 29-0.0412 ± 0.115060.0341 ± 0.07457
PrimaryChange From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · femtoliters (fL)
Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Levels
femtoliters (fL)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline91.36 ± 7.65191.50 ± 4.785
CFB at Infusion: 0-24 hours0.68 ± 1.773-0.42 ± 0.950
CFB at Infusion: 25-48 hours0.65 ± 2.202-0.82 ± 1.487
CFB at Infusion: 49-72 hours0.46 ± 2.168-1.12 ± 1.314
CFB at Infusion: 73-96 hours0.38 ± 2.202-1.04 ± 1.146
CFB at Infusion: 97-120 hours0.47 ± 2.5600.10 ± 1.954
CFB at Acute Follow-up: 121-144 hours0.70 ± 2.3620.76 ± 1.977
CFB at Acute Follow-up: 145-168 hours1.60 ± 3.2700.36 ± 1.230
CFB at Extended Follow-up: Day 81.30 ± 3.5071.08 ± 1.090
CFB at Extended Follow-up: Day 151.20 ± 4.3372.25 ± 4.124
CFB at Extended Follow-up: Day 220.29 ± 5.6750.75 ± 3.747
CFB at Extended Follow-up: Day 29-0.96 ± 5.3154.27 ± 1.775
PrimaryChange From Baseline in Hematology Parameter: Erythrocyte Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocyte levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^6 cells per microliter
Change From Baseline in Hematology Parameter: Erythrocyte Levels
10^6 cells per microliterSAGE-547 Standard DoseSAGE-547 High Dose
Baseline3.261 ± 0.71523.406 ± 0.5297
CFB at Infusion: 0-24 hours-0.078 ± 0.3236-0.022 ± 0.1816
CFB at Infusion: 25-48 hours-0.106 ± 0.4059-0.184 ± 0.2799
CFB at Infusion: 49-72 hours-0.162 ± 0.4112-0.218 ± 0.2072
CFB at Infusion: 73-96 hours-0.175 ± 0.4261-0.132 ± 0.3041
CFB at Infusion: 97-120 hours-0.152 ± 0.3718-0.158 ± 0.5079
CFB at Acute Follow-up: 121-144 hours-0.259 ± 0.4001-0.256 ± 0.5786
CFB at Acute Follow-up: 145-168 hours-0.199 ± 0.3819-0.200 ± 0.7139
CFB at Extended Follow-up: Day 8-0.196 ± 0.4508-0.463 ± 0.4367
CFB at Extended Follow-up: Day 150.115 ± 0.7317-0.133 ± 0.5821
CFB at Extended Follow-up: Day 220.285 ± 0.94240.105 ± 0.3493
CFB at Extended Follow-up: Day 290.607 ± 0.47540.248 ± 0.2924
PrimaryChange From Baseline in Hematology Parameter: Hematocrit Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hematocrit levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · proportion of 1.0 (in liters)
Change From Baseline in Hematology Parameter: Hematocrit Levels
proportion of 1.0 (in liters)SAGE-547 Standard DoseSAGE-547 High Dose
Baseline0.2955 ± 0.056010.3110 ± 0.05443
CFB at Infusion: 0-24 hours-0.0042 ± 0.02561-0.0028 ± 0.01591
CFB at Infusion: 25-48 hours-0.0058 ± 0.03430-0.0192 ± 0.02013
CFB at Infusion: 49-72 hours-0.0123 ± 0.03371-0.0238 ± 0.01487
CFB at Infusion: 73-96 hours-0.0131 ± 0.03564-0.0142 ± 0.02860
CFB at Infusion: 97-120 hours-0.0108 ± 0.03167-0.0160 ± 0.04813
CFB at Acute Follow-up: 121-144 hours-0.0209 ± 0.03369-0.0238 ± 0.05369
CFB at Acute Follow-up: 145-168 hours-0.0135 ± 0.03487-0.0182 ± 0.06883
CFB at Extended Follow-up: Day 8-0.0142 ± 0.03823-0.0375 ± 0.04888
CFB at Extended Follow-up: Day 150.0143 ± 0.05903-0.0058 ± 0.05967
CFB at Extended Follow-up: Day 220.0188 ± 0.061860.0128 ± 0.03157
CFB at Extended Follow-up: Day 290.0516 ± 0.042410.0370 ± 0.02670
PrimaryChange From Baseline in Hematology Parameter: Hemoglobin Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hemoglobin levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · g/L
Change From Baseline in Hematology Parameter: Hemoglobin Levels
g/LSAGE-547 Standard DoseSAGE-547 High Dose
Baseline97.3 ± 19.93100.4 ± 18.28
CFB at Infusion: 0-24 hours-2.1 ± 9.96-0.8 ± 5.26
CFB at Infusion: 25-48 hours-3.8 ± 11.81-3.4 ± 4.77
CFB at Infusion: 49-72 hours-5.2 ± 12.37-5.8 ± 4.21
CFB at Infusion: 73-96 hours-5.8 ± 12.89-4.0 ± 7.97
CFB at Infusion: 97-120 hours-5.4 ± 11.54-4.4 ± 14.99
CFB at Acute Follow-up: 121-144 hours-8.8 ± 12.69-7.2 ± 16.75
CFB at Acute Follow-up: 145-168 hours-6.8 ± 12.78-5.6 ± 20.67
CFB at Extended Follow-up: Day 8-6.7 ± 14.41-12.3 ± 12.97
CFB at Extended Follow-up: Day 152.7 ± 22.10-2.0 ± 18.65
CFB at Extended Follow-up: Day 223.8 ± 21.368.3 ± 12.58
CFB at Extended Follow-up: Day 2915.3 ± 14.509.5 ± 9.26
PrimaryChange From Baseline in Hematology Parameter: Leukocyte Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in leukocyte levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^3 cells/uL
Change From Baseline in Hematology Parameter: Leukocyte Levels
10^3 cells/uLSAGE-547 Standard DoseSAGE-547 High Dose
Baseline11.383 ± 4.350316.538 ± 8.5348
CFB at Infusion: 0-24 hours1.438 ± 2.5891-0.902 ± 2.4833
CFB at Infusion: 25-48 hours0.186 ± 4.5526-3.306 ± 4.7047
CFB at Infusion: 49-72 hours-0.227 ± 6.1765-3.090 ± 5.5029
CFB at Infusion: 73-96 hours-0.577 ± 7.1508-3.798 ± 5.5846
CFB at Infusion: 97-120 hours0.591 ± 10.3636-3.964 ± 5.3646
CFB at Acute Follow-up: 121-144 hours-1.002 ± 8.9938-1.306 ± 7.5940
CFB at Acute Follow-up: 145-168 hours-0.123 ± 10.4153-1.652 ± 7.3674
CFB at Extended Follow-up: Day 8-1.145 ± 7.3294-2.188 ± 6.7041
CFB at Extended Follow-up: Day 15-1.692 ± 5.0282-6.118 ± 7.0178
CFB at Extended Follow-up: Day 22-1.132 ± 4.3853-7.248 ± 7.3886
CFB at Extended Follow-up: Day 29-0.790 ± 6.1582-5.840 ± 4.6825
PrimaryChange From Baseline in Hematology Parameter: Lymphocyte Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocyte levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^3 cells/uL
Change From Baseline in Hematology Parameter: Lymphocyte Levels
10^3 cells/uLSAGE-547 Standard DoseSAGE-547 High Dose
Baseline1.791 ± 0.80432.323 ± 0.5193
CFB at Infusion: 0-24 hours0.213 ± 0.8923-0.470 ± 0.2427
CFB at Infusion: 25-48 hours0.189 ± 1.3559-1.147 ± 0.9771
CFB at Infusion: 49-72 hours0.302 ± 1.0584-0.640 ± 1.1037
CFB at Infusion: 73-96 hours0.200 ± 1.1580-0.780 ± 0.4358
CFB at Infusion: 97-120 hours0.428 ± 1.1946-0.777 ± 0.6516
CFB at Acute Follow-up: 121-144 hours0.152 ± 0.9193-0.987 ± 1.0040
CFB at Acute Follow-up: 145-168 hours0.360 ± 0.8965-1.013 ± 0.8799
CFB at Extended Follow-up: Day 80.482 ± 0.8724-0.700 ± 0.6720
CFB at Extended Follow-up: Day 150.392 ± 0.8363-1.140 ± 0.9334
CFB at Extended Follow-up: Day 220.343 ± 0.6667-2.200
CFB at Extended Follow-up: Day 290.427 ± 0.8182-0.845 ± 1.0677
PrimaryChange From Baseline in Hematology Parameter: Lymphocytes to Leukocytes Ratio Reported in Percentage of Cells

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · percentage of cells
Change From Baseline in Hematology Parameter: Lymphocytes to Leukocytes Ratio Reported in Percentage of Cells
percentage of cellsSAGE-547 Standard DoseSAGE-547 High Dose
Baseline10.67 ± 7.0246.50 ± 7.778
CFB at Infusion: 0-24 hours-1.00 ± 0.0004.00
CFB at Infusion: 25-48 hours-2.50 ± 2.1218.00
CFB at Infusion: 49-72 hours0.67 ± 5.03310.00
CFB at Infusion: 73-96 hours-5.50 ± 4.9506.00
CFB at Infusion: 97-120 hours-4.50 ± 6.3648.00
CFB at Acute Follow-up: 121-144 hours-6.00 ± 4.2431.00
CFB at Acute Follow-up: 145-168 hours-6.00 ± 2.8281.00
CFB at Extended Follow-up: Day 8-6.00 ± 1.414—
CFB at Extended Follow-up: Day 15-3.50 ± 3.536—
CFB at Extended Follow-up: Day 227.00 ± 4.24311.00
CFB at Extended Follow-up: Day 290.50 ± 2.121—
PrimaryChange From Baseline in Hematology Parameter: Monocyte Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocyte levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^3 cells/uL
Change From Baseline in Hematology Parameter: Monocyte Levels
10^3 cells/uLSAGE-547 Standard DoseSAGE-547 High Dose
Baseline0.6182 ± 0.269661.2567 ± 0.83584
CFB at Infusion: 0-24 hours0.2720 ± 0.391370.3470 ± 0.83703
CFB at Infusion: 25-48 hours0.2830 ± 0.54878-0.1200 ± 1.05399
CFB at Infusion: 49-72 hours0.1267 ± 0.52906-0.0667 ± 0.06110
CFB at Infusion: 73-96 hours0.2978 ± 0.444090.4533 ± 0.39068
CFB at Infusion: 97-120 hours0.2322 ± 0.423640.1300 ± 0.96016
CFB at Acute Follow-up: 121-144 hours0.2856 ± 0.47710-0.1400 ± 0.34176
CFB at Acute Follow-up: 145-168 hours0.2800 ± 0.39418-0.4533 ± 0.36295
CFB at Extended Follow-up: Day 80.1900 ± 0.24850-0.2400 ± 0.72194
CFB at Extended Follow-up: Day 150.1767 ± 0.41602-0.1100 ± 1.99404
CFB at Extended Follow-up: Day 220.3029 ± 0.637461.7000
CFB at Extended Follow-up: Day 290.0414 ± 0.213960.4850 ± 0.44548
PrimaryChange From Baseline in Hematology Parameter: Monocytes to Leukocytes Ratio Reported in Percentage of Cells

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · percentage of cells
Change From Baseline in Hematology Parameter: Monocytes to Leukocytes Ratio Reported in Percentage of Cells
percentage of cellsSAGE-547 Standard DoseSAGE-547 High Dose
Baseline7.67 ± 5.5085.00 ± 4.243
CFB at Infusion: 0-24 hours2.00 ± 0.0001.00
CFB at Infusion: 25-48 hours-5.50 ± 7.77813.00
CFB at Infusion: 49-72 hours-2.33 ± 0.57715.00
CFB at Infusion: 73-96 hours-4.50 ± 4.9508.00
CFB at Infusion: 97-120 hours-6.50 ± 9.1928.00
CFB at Acute Follow-up: 121-144 hours-6.50 ± 9.192-1.00
CFB at Acute Follow-up: 145-168 hours-7.00 ± 9.899-2.00
CFB at Extended Follow-up: Day 8-3.00 ± 8.485—
CFB at Extended Follow-up: Day 15-4.50 ± 6.364—
CFB at Extended Follow-up: Day 22-2.50 ± 4.9500.00
CFB at Extended Follow-up: Day 29-5.50 ± 9.192—
PrimaryChange From Baseline in Hematology Parameter: Neutrophil Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophil levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^3 cells/uL
Change From Baseline in Hematology Parameter: Neutrophil Levels
10^3 cells/uLSAGE-547 Standard DoseSAGE-547 High Dose
Baseline7.957 ± 4.150513.863 ± 8.8017
CFB at Infusion: 0-24 hours0.152 ± 2.4078-0.043 ± 1.7435
CFB at Infusion: 25-48 hours-0.552 ± 3.1815-0.783 ± 2.9957
CFB at Infusion: 49-72 hours-1.406 ± 3.4517-0.167 ± 7.0002
CFB at Infusion: 73-96 hours-1.727 ± 3.6351-1.620 ± 6.0920
CFB at Infusion: 97-120 hours-0.743 ± 3.3970-2.653 ± 5.7315
CFB at Acute Follow-up: 121-144 hours-1.848 ± 4.2871-4.247 ± 6.7336
CFB at Acute Follow-up: 145-168 hours-1.440 ± 4.1338-3.517 ± 7.8465
CFB at Extended Follow-up: Day 8-1.731 ± 4.4360-1.953 ± 7.7993
CFB at Extended Follow-up: Day 15-2.372 ± 4.3518-9.825 ± 6.9650
CFB at Extended Follow-up: Day 22-0.877 ± 3.2310-10.645 ± 7.9832
CFB at Extended Follow-up: Day 29-1.590 ± 2.6196-6.323 ± 3.8800
PrimaryChange From Baseline in Hematology Parameter: Neutrophils to Leukocytes Ratio Reported in Percentage of Cells

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · percentage of cells
Change From Baseline in Hematology Parameter: Neutrophils to Leukocytes Ratio Reported in Percentage of Cells
percentage of cellsSAGE-547 Standard DoseSAGE-547 High Dose
Baseline75.67 ± 11.24071.00 ± 8.485
CFB at Infusion: 0-24 hours-3.50 ± 9.19219.00
CFB at Infusion: 25-48 hours5.00 ± 5.6576.00
CFB at Infusion: 49-72 hours5.67 ± 10.5043.00
CFB at Infusion: 73-96 hours11.00 ± 11.3142.00
CFB at Infusion: 97-120 hours13.50 ± 17.6789.00
CFB at Acute Follow-up: 121-144 hours15.00 ± 14.14231.00
CFB at Acute Follow-up: 145-168 hours11.00 ± 8.48525.00
CFB at Extended Follow-up: Day 811.00 ± 11.314—
CFB at Extended Follow-up: Day 157.50 ± 9.192—
CFB at Extended Follow-up: Day 22-4.00 ± 7.071-10.00
CFB at Extended Follow-up: Day 296.50 ± 14.849—
PrimaryChange From Baseline in Hematology Parameter: Platelet Levels

Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in platelet levels is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · 10^3 cells/uL
Change From Baseline in Hematology Parameter: Platelet Levels
10^3 cells/uLSAGE-547 Standard DoseSAGE-547 High Dose
Baseline260.76 ± 95.417284.20 ± 80.707
CFB at Infusion: 0-24 hours2.93 ± 68.82121.40 ± 40.265
CFB at Infusion: 25-48 hours17.38 ± 92.85434.40 ± 69.263
CFB at Infusion: 49-72 hours21.59 ± 109.99558.00 ± 95.533
CFB at Infusion: 73-96 hours31.92 ± 112.96377.80 ± 89.461
CFB at Infusion: 97-120 hours57.49 ± 125.27764.80 ± 101.043
CFB at Acute Follow-up: 121-144 hours63.04 ± 138.41561.80 ± 106.767
CFB at Acute Follow-up: 145-168 hours81.98 ± 141.65050.80 ± 130.555
CFB at Extended Follow-up: Day 858.33 ± 120.43648.75 ± 136.231
CFB at Extended Follow-up: Day 15153.89 ± 166.91987.25 ± 177.265
CFB at Extended Follow-up: Day 2286.35 ± 204.82749.75 ± 75.292
CFB at Extended Follow-up: Day 2925.76 ± 118.99656.75 ± 112.512
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate

ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in heart rate is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · beats/min
Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate
beats/minSAGE-547 Standard DoseSAGE-547 High Dose
Baseline84.3 ± 13.3184.3 ± 19.64
CFB at Infusion: 0-24 hours-1.4 ± 16.87-6.8 ± 8.54
CFB at Infusion: 25-48 hours-0.9 ± 16.58-1.2 ± 6.85
CFB at Infusion: 49-72 hours10.9 ± 21.74-6.5 ± 22.28
CFB at Infusion: 73-96 hours9.7 ± 15.497.7 ± 18.48
CFB at Infusion: 97-120 hours15.9 ± 15.377.0 ± 19.62
CFB at Acute Follow-up: 121-144 hours13.2 ± 14.2511.7 ± 22.76
CFB at Acute Follow-up: 145-168 hours16.6 ± 16.9117.0 ± 26.47
CFB at Extended Follow-up: Day 819.2 ± 16.005.5 ± 22.87
CFB at Extended Follow-up: Day 1515.0 ± 23.095.5 ± 13.13
CFB at Extended Follow-up: Day 2213.8 ± 20.714.3 ± 26.73
CFB at Extended Follow-up: Day 298.6 ± 13.607.0 ± 31.19
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval and QTc Interval

ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in PR interval, QT interval, QRS duration and QTc interval is reported in this outcome measure.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Median · milliseconds (msec)
Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval and QTc Interval
milliseconds (msec)SAGE-547 Standard DoseSAGE-547 High Dose
PR interval: Baseline151.0 (118 to 192)151.0 (132 to 182)
PR interval: CFB at Infusion: 0-24 hours2.0 (-40 to 10)-2.0 (-16 to 18)
PR interval: CFB at Infusion: 25-48 hours3.0 (-40 to 148)3.0 (-4 to 15)
PR interval: CFB at Infusion: 49-72 hours-13.0 (-42 to 16)-2.0 (-8 to 18)
PR interval: CFB at Infusion: 73-96 hours-2.0 (-22 to 22)-4.0 (-6 to 7)
PR interval: CFB at Infusion: 97-120 hours-12.0 (-32 to 68)2.0 (-22 to 26)
PR interval: CFB at Acute Follow-up: 121-144 hours-8.0 (-25 to 23)3.5 (-28 to 12)
PR interval: CFB at Acute Follow-up: 145-168 hours-11.0 (-38 to 14)-2.0 (-26 to 24)
PR interval: CFB at Extended Follow-up: Day 8-10.0 (-30 to 4)0.0 (-20 to 2)
PR interval: CFB at Extended Follow-up: Day 150.0 (-54 to 26)4.0 (-16 to 18)
PR interval: CFB at Extended Follow-up: Day 222.0 (-26 to 36)-6.5 (-40 to 10)
PR interval: CFB at Extended Follow-up: Day 292.0 (-20 to 14)-8.0 (-18 to 22)
QRS Interval: Baseline85.0 (66 to 118)78.0 (40 to 100)
QRS Interval: CFB at Infusion: 0-24 hours1.0 (-12 to 14)1.5 (-4 to 20)
QRS Interval: CFB at Infusion: 25-48 hours0.0 (-14 to 40)-1.0 (-8 to 6)
QRS Interval: CFB at Infusion: 49-72 hours-3.0 (-20 to 6)2.0 (-2 to 5)
QRS Interval: CFB at Infusion: 73-96 hours0.0 (-16 to 18)0.0 (-6 to 20)
QRS Interval: CFB at Infusion: 97-120 hours-4.0 (-32 to 14)0.0 (-14 to 20)
QRS Interval: CFB at Acute Follow-up: 121-144 hours-2.0 (-32 to 8)0.0 (-14 to 20)
QRS Interval: CFB at Acute Follow-up: 145-168 hours-6.0 (-28 to 16)-3.0 (-94 to 20)
QRS Interval: CFB at Extended Follow-up: Day 8-2.0 (-28 to 0)-3.5 (-16 to 0)
QRS Interval: CFB at Extended Follow-up: Day 15-5.0 (-47 to 6)2.0 (-2 to 40)
QRS Interval: CFB at Extended Follow-up: Day 22-4.0 (-26 to 6)-1.0 (-4 to 20)
QRS Interval: CFB at Extended Follow-up: Day 292.0 (-26 to 12)5.0 (-4 to 40)
QT Interval: Baseline363.0 (304 to 476)372.0 (280 to 462)
QT Interval: CFB at Infusion: 0-24 hours19.5 (-84 to 200)24.5 (-26 to 49)
QT Interval: CFB at Infusion: 25-48 hours19.5 (-102 to 236)3.0 (-40 to 30)
QT Interval: CFB at Infusion: 49-72 hours1.0 (-168 to 238)-14.0 (-66 to 144)
QT Interval: CFB at Infusion: 73-96 hours-4.0 (-62 to 128)0.0 (-76 to 118)
QT Interval: CFB at Infusion: 97-120 hours-34.0 (-164 to 72)-36.0 (-102 to 66)
QT Interval: CFB at Acute Follow-up: 121-144 hours-28.0 (-168 to 238)-32.0 (-126 to 40)
QT Interval: CFB at Acute Follow-up: 145-168 hours-32.0 (-164 to 74)-34.0 (-156 to 18)
QT Interval: CFB at Extended Follow-up: Day 8-36.0 (-186 to 42)-35.0 (-138 to -6)
QT Interval: CFB at Extended Follow-up: Day 15-32.0 (-176 to 72)-8.0 (-116 to 16)
QT Interval: CFB at Extended Follow-up: Day 22-28.0 (-132 to 51)-22.0 (-102 to 24)
QT Interval: CFB at Extended Follow-up: Day 29-28.0 (-132 to 29)-63.0 (-96 to 80)
QTc Interval: Baseline435.5 (321 to 531)438.5 (393 to 454)
QTc Interval: CFB at Infusion: 0-24 hours7.5 (-55 to 219)7.0 (-58 to 42)
QTc Interval: CFB at Infusion: 25-48 hours11.5 (-49 to 277)-12.5 (-59 to 29)
QTc Interval: CFB at Infusion: 49-72 hours3.5 (-103 to 275)-14.0 (-38 to 36)
QTc Interval: CFB at Infusion: 73-96 hours8.0 (-30 to 145)-13.5 (-41 to 152)
QTc Interval: CFB at Infusion: 97-120 hours-2.0 (-88 to 106)-17.0 (-38 to 43)
QTc Interval: CFB at Acute Follow-up: 121-144 hours-12.0 (-87 to 319)-9.0 (-31 to 10)
QTc Interval: CFB at Acute Follow-up: 145-168 hours-4.0 (-96 to 93)-17.5 (-52 to 15)
QTc Interval: CFB at Extended Follow-up: Day 8-15.0 (-111 to 83)-54.5 (-86 to 14)
QTc Interval: CFB at Extended Follow-up: Day 152.0 (-104 to 71)-6.5 (-50 to 3)
QTc Interval: CFB at Extended Follow-up: Day 22-8.5 (-57 to 51)-33.5 (-37 to -14)
QTc Interval: CFB at Extended Follow-up: Day 29-2.0 (-72 to 51)-19.0 (-51 to 23)
PrimaryNumber of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage

Prior AEDs and Pressors are those medications that ended before the initiation of SAGE-547 infusion.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage
ParticipantsSAGE-547 Standard DoseSAGE-547 High Dose
Number of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage164
SecondaryNumber of Participants With Relapse - Re-Initiation of Third-Line Agent

Relapse of participants is defined as successfully weaning from a continuous IV third-line agent but subsequent requirement of re-initiation of a third-line agent following conclusion of SAGE-547 treatment.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Relapse - Re-Initiation of Third-Line Agent
ParticipantsSAGE-547 Standard DoseSAGE-547 High Dose
Number of Participants With Relapse - Re-Initiation of Third-Line Agent51
SecondaryNumber of Participants With Treatment Response (Treatment Responders)

A responder was defined as a participant for whom it was not required to re-initiate continuous IV third-line therapy for refractory seizure control during the administration of SAGE-547 at the maintenance dose (prior to SAGE-547 taper infusion).

Time frame:
Up to 96 hours
Reported as:
Count of participants · Participants
Number of Participants With Treatment Response (Treatment Responders)
ParticipantsSAGE-547 Standard DoseSAGE-547 High Dose
Number of Participants With Treatment Response (Treatment Responders)134
SecondaryDuration of Response

Duration of response was defined as the time from the stop date/time of SAGE-547 maintenance to re-initiation of a third-line agent. If no re-initiation of a third-line agent was required, duration of response was not estimable and censored at Day 29 or death date, whichever occurred first. Kaplan-Meier method was used for the analysis.

Time frame:
Up to Day 29
Reported as:
Median · days
Duration of Response
daysSAGE-547 Standard DoseSAGE-547 High Dose
Duration of ResponseNA (NA to NA)NA (NA to NA)
SecondaryMaximum Plasma Concentration (Cmax) of SAGE-547
Time frame:
Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of SAGE-547
nanograms per milliliter (ng/mL)SAGE-547 Standard DoseSAGE-547 High Dose
Maximum Plasma Concentration (Cmax) of SAGE-547144.24 ± 65.263200.82 ± 71.000
SecondaryTime to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-547
Time frame:
Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Reported as:
Median · hours
Time to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-547
hoursSAGE-547 Standard DoseSAGE-547 High Dose
Time to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-5471.010 (0.92 to 96.00)60.150 (0.93 to 118.52)
SecondaryAreas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast)
Time frame:
Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Reported as:
Mean · hour*nanograms per milliliter (h*ng/mL)
Areas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast)
hour*nanograms per milliliter (h*ng/mL)SAGE-547 Standard DoseSAGE-547 High Dose
Areas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast)7677.6 ± 2668.0614260.0 ± 5048.01
SecondaryArea Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24)
Time frame:
Pre-dose (0 hours), 1, 2, 4, 8 and 24 hours post-dose
Reported as:
Mean · h*ng/mL
Area Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24)
h*ng/mLSAGE-547 Standard DoseSAGE-547 High Dose
Area Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24)1590.3 ± 524.582728.3 ± 1010.14
SecondaryArea Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96)
Time frame:
Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose
Reported as:
Mean · h*ng/mL
Area Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96)
h*ng/mLSAGE-547 Standard DoseSAGE-547 High Dose
Area Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96)6290.6 ± 2080.0410801.7 ± 4006.70
SecondaryAverage Plasma Concentration (Cav) of SAGE-547
Time frame:
Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose
Reported as:
Mean · ng/mL
Average Plasma Concentration (Cav) of SAGE-547
ng/mLSAGE-547 Standard DoseSAGE-547 High Dose
Average Plasma Concentration (Cav) of SAGE-54766.22 ± 21.929113.62 ± 42.079
SecondaryPlasma Clearance (CL) of SAGE-547

Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.

Time frame:
Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose
Reported as:
Mean · liters per hour per kilogram (L/h/kg)
Plasma Clearance (CL) of SAGE-547
liters per hour per kilogram (L/h/kg)SAGE-547 Standard DoseSAGE-547 High Dose
Plasma Clearance (CL) of SAGE-5471.3999 ± 0.545251.2487 ± 0.65351
SecondaryChange From Baseline in Modified Rankin Scale (mRS-9Q) Scores

The mRS-9Q is a commonly used scale to determine disability and functional dependence due to neurological insult such as a stroke. It is a shortened version consisting of 9 questions. The score was categorized on the scale of 0 to 5 (0 = No symptoms, 1 = No significant disability, able to carry out all usual activities, despite some symptoms, 2 = Slight disability, able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability, requires some help, but able to walk unassisted, 4 = Moderately severe disability, unable to attend to own bodily needs without assistance or unable to walk unassisted, and 5 = Severe disability, requires constant nursing care and attention, bedridden). Higher scores indicated worsening of symptoms.

Time frame:
Baseline (Screening) to Infusion at 49-72 hour, 73-96 hour; Extended follow-up at Day 8, 15, 22 and 29
Reported as:
Mean · score on a scale
Change From Baseline in Modified Rankin Scale (mRS-9Q) Scores
score on a scaleSAGE-547 Standard DoseSAGE-547 High Dose
Baseline5.0 ± 0.005.0 ± 0.00
CBF at Infusion: 49-72 hours0.0 ± 0.000.0 ± 0.00
CFB at Infusion: 73-96 hours0.0 ± 0.000.0 ± 0.00
CFB at Extended Follow-up: Day 8-0.1 ± 0.260.0 ± 0.00
CFB at Extended Follow-up: Day 15-0.1 ± 0.35-0.3 ± 0.50
CFB at Extended Follow-up: Day 22-0.4 ± 0.74-0.5 ± 0.58
CFB at Extended Follow-up: Day 29-0.9 ± 1.50-1.0 ± 1.41
SecondaryChange From Baseline in Clinical Global Impression: Severity Scale (CGI-S)

The CGI-Severity (CGI-S) scale employs a 7-point Likert scale to assess the severity of participant's current illness state. Clinician responded to a question "Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?" on the following scores: 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, and 7 = Among the most extremely ill, where higher score = more affected.

Time frame:
Baseline (Screening), Extended follow-up at Days 8, 15, 22, and 29
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression: Severity Scale (CGI-S)
score on a scaleSAGE-547 Standard DoseSAGE-547 High Dose
Baseline6.9 ± 0.256.8 ± 0.41
CFB at Extended Follow-up: Day 8-1.1 ± 1.06-1.2 ± 1.30
CFB at Extended Follow-up: Day 15-2.3 ± 1.22-1.8 ± 1.79
CFB at Extended Follow-up: Day 22-2.7 ± 1.63-2.4 ± 1.82
CFB at Extended Follow-up: Day 29-3.0 ± 1.96-2.8 ± 2.39
SecondaryClinical Global Impression: Improvement Scale (CGI-I) Scores

The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse; where higher scores indicated worst outcomes. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.

Time frame:
Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · score on a scale
Clinical Global Impression: Improvement Scale (CGI-I) Scores
score on a scaleSAGE-547 Standard DoseSAGE-547 High Dose
Infusion: 0-24 hours4.0 ± 0.374.0 ± 0.00
Infusion: 25-48 hours4.0 ± 0.524.5 ± 0.84
Infusion: 49-72 hours3.6 ± 0.813.6 ± 0.89
Infusion: 73-96 hours3.1 ± 0.813.7 ± 1.37
Infusion: 97-120 hours2.9 ± 0.813.0 ± 1.10
Acute Follow-up: 121-144 hours3.3 ± 1.304.0 ± 1.41
Acute Follow-up: 145-168 hours3.2 ± 1.523.2 ± 1.92
Extended Follow-up: Day 82.9 ± 1.532.8 ± 1.10
Extended Follow-up: Day 152.2 ± 1.212.4 ± 1.14
Extended Follow-up: Day 222.3 ± 1.582.6 ± 1.95
Extended Follow-up: Day 292.6 ± 1.892.4 ± 2.61
SecondaryChange From Baseline in Glasgow Coma Scale (GCS) Scores

The Glasgow Coma Scale is divided into three components which are scored separately: ocular response (assessment 1-4 points), motor response (assessment 1-6 points), verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total score that will range between a minimum of 3 points (which corresponds to a participant who does not open his/her eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a participant with open eyes, obeying orders and maintaining a consistent language). It has been considered that the GCS score between 15 and 13 points corresponds to a slight alteration of consciousness, a score of 12-9 points with moderate impairment and 8 points or less with a serious deterioration in level of consciousness.

Time frame:
Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · score on a scale
Change From Baseline in Glasgow Coma Scale (GCS) Scores
score on a scaleSAGE-547 Standard DoseSAGE-547 High Dose
Baseline3.9 ± 1.883.5 ± 1.22
CFB at Infusion: 0-24 hours-0.4 ± 1.26-0.2 ± 0.45
CFB at Infusion: 25-48 hours-0.6 ± 1.63-0.5 ± 1.22
CFB at Infusion: 49-72 hours0.9 ± 2.211.4 ± 1.34
CFB at Infusion: 73-96 hours1.1 ± 2.161.3 ± 2.42
CFB at Infusion: 97-120 hours2.4 ± 3.163.0 ± 3.69
CFB at Acute Follow-up: 121-144 hours3.3 ± 3.303.3 ± 3.93
CFB at Acute Follow-up: 145-168 hours3.9 ± 3.985.0 ± 4.90
CFB at Extended Follow-up: Day 83.9 ± 4.535.0 ± 4.90
CFB at Extended Follow-up: Day 156.7 ± 4.735.4 ± 5.27
CFB at Extended Follow-up: Day 226.9 ± 4.996.4 ± 4.83
CFB at Extended Follow-up: Day 296.1 ± 5.707.4 ± 4.67
SecondaryChange From Baseline in Richmond Agitation Sedation Scale (RASS) Score

The RASS was an assessment of agitation and sedation in hospitalized participants, using a 10 point scale (ranged from -5 to +4), where, -5 = Unarousable, -4 = Deep sedation, -3 = Moderate sedation, -2 = Light sedation, -1 = Drowsy, 0 = Alert and calm, +1 = Restless, +2 = Agitated, +3 = Very agitated and +4 = Combative. Lower scores signify higher levels of sedation and higher scores signify heightened agitation. Participant in a calm and alert state would score a 0.

Time frame:
Baseline (Screening) to Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29
Reported as:
Mean · score on a scale
Change From Baseline in Richmond Agitation Sedation Scale (RASS) Score
score on a scaleSAGE-547 Standard DoseSAGE-547 High Dose
Baseline-4.8 ± 0.54-4.8 ± 0.41
CFB at Infusion: 0-24 hours-0.1 ± 0.250.0 ± 0.00
CFB at Infusion: 25-48 hours-0.1 ± 0.440.0 ± 0.00
CFB at Infusion: 49-72 hours0.5 ± 1.320.8 ± 1.30
CFB at Infusion: 73-96 hours0.9 ± 1.410.7 ± 1.21
CFB at Infusion: 97-120 hours1.4 ± 1.591.3 ± 1.75
CFB at Acute Follow-up: 121-144 hours2.0 ± 1.971.3 ± 1.97
CFB at Acute Follow-up: 145-168 hours2.3 ± 2.241.4 ± 1.67
CFB at Extended Follow-up: Day 82.3 ± 2.162.4 ± 2.61
CFB at Extended Follow-up: Day 153.3 ± 1.792.2 ± 1.92
CFB at Extended Follow-up: Day 223.4 ± 1.912.8 ± 2.17
CFB at Extended Follow-up: Day 293.0 ± 2.222.8 ± 2.17
SecondaryNumber of Participants Who Survived

Survival time was defined as duration of survival from screening up to Day 29.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants Who Survived
ParticipantsSAGE-547 Standard DoseSAGE-547 High Dose
Number of Participants Who Survived135

Adverse events

Collected over Up to 29 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAGE-547 Standard Dose5/19 (26.3%)14/19 (73.7%)15/19 (78.9%)
SAGE-547 High Dose1/6 (16.7%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventSAGE-547 Standard DoseSAGE-547 High Dose
SepsisInfections and infestations1/191/6
PeritonitisInfections and infestations0/191/6
HypotensionVascular disorders0/191/6
Multi-organ failureGeneral disorders0/191/6
Metabolic acidosisMetabolism and nutrition disorders0/191/6
Renal failure acuteRenal and urinary disorders1/191/6
Cardiac arrestCardiac disorders0/191/6
RhabdomyolysisMusculoskeletal and connective tissue disorders0/191/6
Respiratory failureRespiratory, thoracic and mediastinal disorders3/190/6
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/190/6
Most frequent other events
Showing 10 of 121
Most frequent other events
EventSAGE-547 Standard DoseSAGE-547 High Dose
HypotensionVascular disorders0/193/6
Urinary tract infectionInfections and infestations1/192/6
Blood creatine phosphokinase increasedInvestigations0/192/6
Lipase increasedInvestigations0/192/6
HypertensionVascular disorders1/192/6
Skin disorderSkin and subcutaneous tissue disorders0/192/6
Sinus tachycardiaCardiac disorders1/192/6
Fungal skin infectionInfections and infestations1/191/6
Oral candidiasisInfections and infestations1/191/6
PneumoniaInfections and infestations1/191/6

Baseline characteristics

Safety population included all participants who were initiated with an infusion of SAGE-547.

Age, Continuous
Age, Continuous(years)SAGE-547 Standard DoseSAGE-547 High DoseTotal
Mean49.3 ± 18.9842.3 ± 22.1147.6 ± 19.52
Sex: Female, Male
Sex: Female, Male(Participants)SAGE-547 Standard DoseSAGE-547 High DoseTotal
Female819
Male11516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SAGE-547 Standard DoseSAGE-547 High DoseTotal
Hispanic or Latino112
Not Hispanic or Latino18523
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SAGE-547 Standard DoseSAGE-547 High DoseTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American426
White15419
More than one race000
Unknown or Not Reported000
08

Study locations

17 sites
  • Sage Investigational Site
    Birmingham, Alabama 35294, United States
  • Sage Investigational Site
    Sarasota, Florida 34239, United States
  • Sage Investigational Site
    Chicago, Illinois 60611, United States
  • Sage Investigational Site
    Wichita, Kansas 67214, United States
  • Sage Investigational Site
    New Orleans, Louisiana 70121, United States
  • Sage Investigational Site
    Boston, Massachusetts 02114, United States
  • Sage Investigational Site
    Boston, Massachusetts 02115, United States
  • Sage Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Sage Investigational Site
    Detroit, Michigan 48322, United States
  • Sage Investigational Site
    New York, New York 10032, United States
  • Sage Investigational Site
    Rochester, New York 14642, United States
  • Sage Investigational Site
    Durham, North Carolina 27710, United States
  • Sage Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Sage Investigational Site
    Nashville, Tennessee 37232, United States
  • Sage Investigational Site
    Dallas, Texas 75251, United States
  • Sage Investigational Site
    Temple, Texas 76504, United States
09

References and documents

Publications

  • Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, Hoffmann E, Colquhoun H, Doherty JJ, Kanes SJ. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017 Sep;82(3):342-352. doi: 10.1002/ana.25008. Epub 2017 Sep 11. PubMed 28779545 ↗

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in May 2015, 13 months.

Results were first posted in May 2022, 7 years after primary completion. A results delay was requested in Apr 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2014
First posted
Feb 3, 2014
StartActual
Mar 21, 2014
Primary completionActual
May 3, 2015
CompletionActual
May 3, 2015
Results delay requested
Apr 25, 2017
Results first posted
May 3, 2022
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02052739
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Mar 21, 2014
Primary completion
May 3, 2015
Completion
May 3, 2015
Results posted
May 3, 2022
Last update
Sep 15, 2025

Study contacts

Robert Lasser, MD, MBA
study chair · Sage Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion